Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study

References

• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015;11:276–89.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
   PubMed Web of Science ®Google Scholar
• Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 2016;75:709–14.
   PubMed Web of Science ®Google Scholar
• Narváez J, Magallares B, Díaz Torné C, Hernández MV, Reina D, Corominas H, et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 2016;45:386–90.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, et al. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. PLoS One 2014;9:e98202.
   PubMed Web of Science ®Google Scholar
• Möller B, Scherer A, Förger F, Villiger PM, Finckh A. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis 2014;73:691–6.
   PubMed Web of Science ®Google Scholar
• Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DPM, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009;68:69–74.
   PubMed Web of Science ®Google Scholar
• Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 2013;43:9–17.
   PubMed Web of Science ®Google Scholar
• Boss B, Neeck G. Correlation of IL-6 with the classical humoral disease activity parameters ESR and CRP and with serum cortisol, reflecting the activity of the HPA axis in active rheumatoid arthritis. Z Rheumatol 2000;59:II/62–4.
   Web of Science ®Google Scholar
• Pavkova Goldbergova M, Pavek N, Lipkova J, Jarkovsky J, Stouracova M, Gatterova J, et al. Circulating cytokine pattern and factors describing rheumatoid arthritis: IL-15 as one of the biomarkers for RA. Biomarkers 2012;17:655–62.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis-shaping the immunological landscape. Nat Rev Rheumatol 2016;12:63–8.
   PubMed Web of Science ®Google Scholar
• Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. Toward a cytokine-based disease taxonomy. Nat Med 2013;19:822–4.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 2018;20:165.
   PubMed Web of Science ®Google Scholar
• Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - the ANSWER cohort study. Arthritis Res Ther 2019;21:91.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013;48:452–8.
   PubMed Web of Science ®Google Scholar
• Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC, et al. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Semin Arthritis Rheum 2020;50:17–24.
   PubMed Web of Science ®Google Scholar
• Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol 2013;42:253–9.
   PubMed Web of Science ®Google Scholar
• Du Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012;71:997–9.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis 2016;75:1321–7.
   PubMed Web of Science ®Google Scholar
• Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford) 2014;53:76–84.
   PubMed Web of Science ®Google Scholar
• Shafran IH, Alasti F, Smolen JS, Aletaha D. Implication of baseline levels and early changes of reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 2020;79:874–82.
   PubMed Web of Science ®Google Scholar
• Forsblad-d’Elia H, Bengtsson K, Kristensen LE, Jacobsson LTH. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford) 2015;54:1186–93.
   PubMed Web of Science ®Google Scholar
• Wang J, Devenport J, Low JM, Yu D, Hitraya E. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:882–5.
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, et al. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology (Oxford) 2016;55:1466–76.
   PubMed Web of Science ®Google Scholar
• Conigliaro P, Triggianese P, Chimenti MS, Tonelli M, Sunzini F, Kroegler B, et al. Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors. Isr Med Assoc J 2017;19:467–72.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Strand V, FitzGerald O, Ahmad HA, Elbez Y, et al. Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. Rheumatol Int 2020;40:1021–8.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328–37.
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521–8.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162–6.
   PubMed Web of Science ®Google Scholar
• Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, et al. High serum interleukin-6 is associated with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis. Arthritis Rheum 2020;72:1456–66.
   PubMed Web of Science ®Google Scholar
• Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifyin. Ann Rheum Dis 2018;77:1276–82.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish. Arthritis Rheum 2010;62:22–32.
   PubMed Web of Science ®Google Scholar
• Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeniet F, et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. Clin Rheumatol 2018;37:315–21.
   PubMed Web of Science ®Google Scholar